Neuroactive steroids as modulators of depression and anxiety

References

• Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci.22(9), 410–416 (1999).
   PubMed Web of Science ®Google Scholar
• Mensah-Nyagan AG, Do-Rego JL, Beaujean D, Luu-The,V, Pelletier G, Vaudry H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol. Rev.51(1), 63–81 (1999).
   PubMed Web of Science ®Google Scholar
• Crawley JN, Glowa JR, Majewska MD, Paul SM. Anxiolytic activity of an endogenous adrenal steroid. Brain Res.398, 382–385 (1986).
   PubMed Web of Science ®Google Scholar
• Paul SM, Purdy RH. Neuroactive steroids. FASEB J.6, 2311–2322 (1992).
   PubMed Web of Science ®Google Scholar
• Rupprecht R. The neuropsychopharmacological potential of neuroactive steroids. J. Psychiatr. Res.31, 297–314 (1997).
   PubMed Web of Science ®Google Scholar
• Reddy DS, Kaur G, Kulkarni SK. Sigma (σ1) receptor mediated antidepressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport9(13), 3069–3073 (1998).
   PubMed Web of Science ®Google Scholar
• Urani A, Roman FJ, Phan V-L, Su T-P, Maurice T. The antidepressant-like effect induced by σ1-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J. Pharmacol. Expert Ther.298(3), 1269–1279 (2001).
   PubMed Web of Science ®Google Scholar
• Melchior CL, Ritzmann RF. Pregnenolone and pregnenolone sulfate, alone and with ethanol, in mice on plus-maze. Pharmacol. Biochem. Behav.48(4), 893–897 (1994).
   PubMedGoogle Scholar
• Majewska MD. Neurosteroids: Endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog. Neurobiol.38, 379–395 (1992).
   PubMed Web of Science ®Google Scholar
• Reddy DS, Kulkarni SK. Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice. Brain Res.752, 61–71 (1997).
   PubMedGoogle Scholar
• Jorge JC, Gonzalez L, Fortis A, Cruz ND. Sex-specific modulation of anxiety and locomotion after neonatal exposure to pregnenolone sulfate. Physiol. Behav.83(5), 779–786 (2005).
   PubMed Web of Science ®Google Scholar
• Melchior CL, Ritzmann RF. Dehydroepiandrosterone is an anxiolytic in mice on the plus maze. Pharmacol. Biochem. Behav.47(3), 437–441 (1994).
   PubMed Web of Science ®Google Scholar
• Majewska MD, Demigören S, Spivak CE, London ED. The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res.526, 143–146 (1990).
   PubMed Web of Science ®Google Scholar
• Bitran D, Purdy RH, Kellogg CK. Anxiolytic effect of progesterone is associated with increases in cortical allopregnanolone and GABAA receptor function. Pharmacol. Biochem. Behav.45, 423–428 (1993).
   PubMed Web of Science ®Google Scholar
• Bitran D, Shiekh M, McLeod M. Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanolone at brain GABAA receptors. J. Neuroendocrinol.7, 171–177 (1995).
   PubMed Web of Science ®Google Scholar
• Reddy DS, O’Malley BW, Rogawski MA. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology48(1), 14–24 (2005).
   PubMed Web of Science ®Google Scholar
• Wieland S, Belluzi JD, Stein L, Lan NC. Comparative behavioral characterization of the neuroactive steroids 3α-OH,5α-pregnan-20-one and 3α-OH,5α-pregnan-20-one in rodents. Psychopharmcol.118, 65–71 (1995).
   PubMed Web of Science ®Google Scholar
• Wieland S, Lan NC, Mirasedeghi S, Gee KW. Anxiolytic activity of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Brain Res.565, 263–268 (1991).
   PubMed Web of Science ®Google Scholar
• Rodgers RJ, Johnson NJ. Behaviorally selective effects of neuroactive steroids on plus-maze anxiety in mice. Pharmacol. Biochem. Behav.59(1), 221–232 (1998).
   PubMed Web of Science ®Google Scholar
• Khisti RT, Chopde CT, Jain SP. Antidepressant-like effect of the neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice forced swim test. Pharmacol. Biochem. Behav.67(1), 137–143 (2000).
   PubMed Web of Science ®Google Scholar
• Barbaccia ML, Roscetti G, Trabucchi M et al. Time-dependent changes in rat brain neuroactive steroid concentrations and GABAA receptor function after acute stress. Neuroendocrinology63(2), 166–172 (1996).
   PubMed Web of Science ®Google Scholar
• Patchev VK, Hassan AHS, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology15, 533–541 (1996).
   PubMed Web of Science ®Google Scholar
• Patchev VK, Shoaib M, Holsboer F, Almeida OFX. The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience62(1), 265–271 (1994).
   PubMed Web of Science ®Google Scholar
• Patchev VK, Montkowski A, Rouskova D et al. Neonatal treatment of rats with the neuroactive steroid tetrahydrodeoxy corticosterone (THDOC) abolishes the behavioral and neurondocrine consequences of adverse early life events. J. Clin. Invest.99(5), 962–966 (1997).
   PubMedGoogle Scholar
• Dong E, Matsumoto K, Uzunova V et al. Brain 5α-dihydroprogesterone and allopregnanolone synthesis in a mouse model of protracted social isolation. Proc. Natl Acad. Sci. USA98(5), 2849–2854 (2001).
   PubMed Web of Science ®Google Scholar
• Guidotti A, Dong E, Matsumoto K et al. The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5α-dihydroprogesterone in psychiatric disorders. Brain Res. Brain Res. Rev.37(1–3), 110–115 (2001).
   PubMed Web of Science ®Google Scholar
• Uzunova V, Ceci M, Kohler C, Uzunov DP, Wrynn AS. Region-specific dysregulation of allopregnanolone brain content in the olfactory bulbectomized rat model of depression. Brain Res.976(1), 1–8 (2003).
   PubMedGoogle Scholar
• Uzunova V, Wrynn AS, Kinnunen A et al. Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur. J. Pharmacol.486(1), 31–34 (2004).
   PubMed Web of Science ®Google Scholar
• Serra M, Pisu MG, Muggironi M et al. Opposite effects of short- versus long-term administration of fluoxetine on the concentrations of neuroactive steroids in rat plasma and brain. Psychopharmcoogy.158(1), 48–54 (2001).
   PubMed Web of Science ®Google Scholar
• Uzunov DP, Cooper TB, Costa E, Guidotti A. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc. Natl Acad. Sci. USA93, 12599–12604 (1996).
   PubMed Web of Science ®Google Scholar
• Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl Acad. Sci. USA96(23), 13512–13517 (1999).
   PubMed Web of Science ®Google Scholar
• Trauger JW, Jiang A, Stearns BA, LoGrasso PV. Kinetics of allopregnanolone formation catalyzed by human 3α-hydroxysteroid dehydrogenase type III (AKR1C2). Biochemistry41(45), 13451–13459 (2002).
   PubMed Web of Science ®Google Scholar
• George MS, Guidotti A, Rubinow D et al. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone and DBI. Biol. Psychiatry35, 775–780 (1994).
   PubMed Web of Science ®Google Scholar
• Semeniuk T, Jhangri GS, Le Melledo JM. Neuroactive steroid levels in patients with generalized anxiety disorder. J. Neuropsychiatry Clin. Neurosci.13(3), 396–398 (2001).
   PubMed Web of Science ®Google Scholar
• Heydari B, Le Melledo JM. Low pregnenolone sulphate plasma concentrations in patients with generalized social phobia. Psychol. Med.32(5), 929–933 (2002).
   PubMed Web of Science ®Google Scholar
• Bicikova M, Tallová J, Hill M, Krausova Z, Hampl R. Serum concentrations of some neuroactive steroids in women suffering from mixed anxiety-depressive disorder. Neurochem. Res.25(12), 1623–1627 (2000).
   PubMedGoogle Scholar
• Meieran SE, Reus VI, Webster R, Shafton R, Wolkowitz OM. Chronic pregnenolone effects in normal humans: attenuation of benzodiazepine-induced sedation. Psychoneuroendocrinology29, 486–500 (2003).
   Google Scholar
• Osran H, Reist C, Chen CC, et al. Adrenal androgens and cortisol in major depression. Am. J. Psychiatry150(5), 806–809 (1993).
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, von Muhlen D, Laughlin GA, Kripke A. Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J. Am. Geriatr. Soc.47(6), 685–691 (1999).
   PubMed Web of Science ®Google Scholar
• Goodyer IM, Herbert J, Altham PM. Adrenal steroid secretion and major depression in 8- to 16-year-olds, III. Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression. Psychol. Med.28(2), 265–273 (1998).
   PubMed Web of Science ®Google Scholar
• Fabian TJ, Dew MA, Pollock BG et al. Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults. Biol. Psychiatry50(10), 767–774 (2001).
   PubMed Web of Science ®Google Scholar
• Heuser I, Deuschle M, Luppa P et al. Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J. Clin. Endocrinol. Metab.83(9), 3130–3133 (1998).
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Roberts E et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol. Psychiatry41, 311–318 (1997).
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Keebler A et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry156(4), 646–649 (1999).
   PubMed Web of Science ®Google Scholar
• Schmidt PJ, Daly RC, Bloch M et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch. Gen. Psychiatry62(2), 154–162 (2005).
   PubMed Web of Science ®Google Scholar
• Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biol. Psychiatry45, 1533–1541 (1999).
   PubMed Web of Science ®Google Scholar
• Le Melledo JM, Baker GB. Neuroactive steroids and anxiety disorders. J. Psychiatry Neurosci.27, 161–165 (2002).
   PubMedGoogle Scholar
• Laufer N, Maayan R, Hermesh H et al. Involvement of GABAA receptor modulating neuroactive steroids in patients with social phobia. Psychiatry Res.137(1–2), 131–136 (2005).
   PubMedGoogle Scholar
• Tait GR, McManus K, Bellavance F et al. Neuroactive steroid changes in response to challenge with the panicogenic agent pentagastrin. Psychoneuroendocrinology27(4), 417–429 (2002).
   PubMed Web of Science ®Google Scholar
• Brambilla F, Mellado C, Alciati A et al. Plasma concentrations of anxiolytic neuroactive steroids in men with panic disorder. Psychiatry Res.135(3), 185–190 (2005).
   PubMed Web of Science ®Google Scholar
• Spivak B, Maayan R, Kotler M et al. Elevated circulatory level of GABAA-antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psych. Med.30(3), 1227–1231 (2000).
   Google Scholar
• Sondergaard HP, Hansson LO, Theorell T. Elevated blood levels of dehydroepiandrosterone sulphate vary with symptom load in posttraumatic stress disorder: findings from a longitudinal study of refugees in Sweden. Psychother. Psychosom.71(5), 298–303 (2002).
   PubMed Web of Science ®Google Scholar
• Rasmusson AM, Vasek J, Lipschitz DS et al. An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. Neuropsychopharmacology29(8), 1546–1557 (2004).
   PubMed Web of Science ®Google Scholar
• Pico-Alfonso MA, Garcia-Linares MI, Celda-Navarro N, Herbert J, Martinez M. Changes in cortisol and dehydroepiandrosterone in women victims of physical and psychological intimate partner violence. Biol. Psychiatry56, 233–240 (2004).
   PubMed Web of Science ®Google Scholar
• Butterfield MI, Stechuchak KM, Connor KM et al. Neuroactive steroids and suicidality in posttraumatic stress disorder. Am. J. Psychiatry162(2), 380–382 (2005).
   PubMed Web of Science ®Google Scholar
• Romeo E, Ströhle A, Spalletta G et al. Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry155, 910–913 (1998).
   PubMed Web of Science ®Google Scholar
• Ströhle A, Pasini A, Romeo E et al. Fluoxetine decreases concentrations of 3α, 5α-tetrahydrodeoxycorticosterone (THDOC) in major depression. J. Psychiatr. Res.34, 183–186 (2000).
   PubMed Web of Science ®Google Scholar
• Brambilla F, Biggio G, Pisu MG et al. Plasma concentrations of anxiolytic neurosteroids in men with normal anxiety scores: a correlation analysis. Neuropsychobiology50(1), 6–9 (2004).
   PubMed Web of Science ®Google Scholar
• Brambilla F, Biggio G, Pisu MG et al. Neurosteroid secretion in panic disorder. Psychiatry Res.118(2), 107–116 (2003).
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Spencer-Gardner C, Gotts G et al. Progesterone and the premenstrual syndrome: a double blind crossover trial. Br. Med. J.290, 1617–1621 (1980).
   Google Scholar
• Baker ER, Best RG, Manfredi RL, Demers LM, Wolf GC. Efficacy of progesterone vaginal suppositories in alleviation of nervous symptoms in patients with premenstrual syndrome. J. Assist. Reprod. Genet.12(3), 205–209 (1995).
   PubMed Web of Science ®Google Scholar
• Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. progesterone Study Group. Br. J. Gen. Pract.45(400), 589–593 (1995).
   PubMed Web of Science ®Google Scholar
• Freeman E, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA264(3), 349–353 (1990).
   PubMed Web of Science ®Google Scholar
• Vanselow W, Dennerstein L, Greenwood KM, de Lignieres B. Effect of progesterone and its 5α and 5β metabolites on symptoms of premenstrual syndrome according to route of administration. J. Psychosom. Obstet. Gynaecol.17(1), 29–38 (1996).
   PubMed Web of Science ®Google Scholar
• Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA274(1), 51–57 (1995).
   PubMed Web of Science ®Google Scholar
• Dalton K. Successful prophylactic progesterone for idiopathic postnatal depression. Int. J. Prenatal Perinatal Stud.323–327 (1989).
   Google Scholar
• Lawrie TA, Hofmeyr GJ, De Jager M et al. A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. Br. J. Obstet. Gynaecol.105(10), 1082–1090 (1998).
   PubMedGoogle Scholar
• Uzunova V, Sheline Y, Davis JM et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl Acad. Sci. USA95, 3239–3244 (1998).
   PubMed Web of Science ®Google Scholar
• Maitra R, Reynolds JN. Modulation of GABAA receptor function by neuroactive steroids: evidence for heterogeneity of steroid sensitivity of recombinant GABAA receptor isoforms. Can. J. Physiol. Pharmacol.76, 909–920 (1998).
   PubMedGoogle Scholar
• Schule C, di Michele F, Baghai T et al. Influence of sleep deprivation on neuroactive steroids in major depression. Neuropsychopharmacology28(3), 577–581 (2003).
   PubMed Web of Science ®Google Scholar
• Padberg F, di Michele F, Zwanzger P et al. Plasma concentrations of neuroactive steroids before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Neuropsychopharmacology27(5), 874–878 (2002).
   PubMedGoogle Scholar
• Baghai TC, di Michele F, Schule C et al. Plasma concentrations of neuroactive steroids before and after electroconvulsive therapy in major depression. Neuropsychopharmacology30(6), 1181–1186 (2005).
   PubMedGoogle Scholar
• Schule C, Romeo E, Uzunov DP et al. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3α-hydroxysteroid dehydrogenase activity. Mol. Psychiatry11(3), 261–272 (2005).
   Google Scholar
• Ströhle A, Romeo E, di Michele F et al. GABAA receptor modulatory neuroactive steroid composition in panic disoder and during paroxetine treatment. Am. J. Psychiatry159, 145–147 (2002).
   PubMed Web of Science ®Google Scholar
• Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology28, 139–168 (2003).
   PubMed Web of Science ®Google Scholar
• Strohle A, Romeo E, di Michele F et al. Induced panic attacks shift γ-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch. Gen. Psychiatry60(2), 161–168 (2003).
   PubMed Web of Science ®Google Scholar
• Zwanzger P, Eser D, Padberg F et al. Neuroactive steroids are not affected by panic induction with 50μ cholecystokinin-tetrapeptide (CCK-4) in healthy volunteers. J. Psychiatr. Res.38(2), 215–217 (2004).
   PubMedGoogle Scholar
• Reddy DS. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? Trends Pharmacol. Sci.24(3), 103–106 (2003).
   PubMed Web of Science ®Google Scholar
• Eser D, di Michele F, Zwanzger P et al. Panic induction with cholecystokinin-tetrapeptide (CCK-4) Increases plasma concentrations of the neuroactive steroid 3α, 5αtetrahydrodeoxycorticosterone (3α,5α-THDOC) in healthy volunteers. Neuropsychopharmacology30(1), 192–195 (2005).
   PubMedGoogle Scholar
• Koszycki D, Zacharko RM, Le Mellédo JM, Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers. Depression Anxiety8, 1–7 (1998).
   PubMedGoogle Scholar
• Zwanzger P, Rupprecht R. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J. Psychiatry Neurosci.30(3), 167–175 (2005).
   PubMed Web of Science ®Google Scholar